XBiotech In-licenses Anti-NY-ESO-1 Antibody Targeting Advanced Cancer
XBiotech Inc. (XBIT)
Last xbiotech inc. earnings: 8/9 03:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
xbiotech.com/about/investors.html
Company Research
Source: GlobeNewswire
AUSTIN, Texas, April 02, 2018 (GLOBE NEWSWIRE) -- XBiotech USA, Inc. (NASDAQ:XBIT) announced today that it has obtained an exclusive, worldwide license from CT Atlantic AG (CTA), a Swiss biotechnology company. Under the terms of the license agreement, XBiotech will use its proprietary manufacturing technology to advance the development of the True HumanTM anti-NY-ESO-1 monoclonal antibody, 12D7. Accordingly, XBiotech will now begin to establish the production capability to enable 12D7 clinical development. The 12D7 antibody targets NY-ESO-1, a cancer-related protein commonly found in many kinds of aggressive tumors. The therapeutic use of 12D7 offers the potential to target advanced tumors by activating cellular immunity or antibody directed immune responses against tumors. A 12D7 therapy may be combined with other therapies that unleash the immune system to produce anti-cancer responses. John Simard, President & CEO of XBiotech, commented, “The 12D7 antibody was isolated from
Show less
Read more
Impact Snapshot
Event Time:
XBIT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
XBIT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
XBIT alerts
High impacting XBiotech Inc. news events
Weekly update
A roundup of the hottest topics
XBIT
News
- XBiotech Inc.'s (NASDAQ:XBIT) top owners are retail investors with 44% stake, while 44% is held by insiders [Yahoo! Finance]Yahoo! Finance
- XBiotech Inc. (NASDAQ: XBIT) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- XBiotech Inc. (NASDAQ: XBIT) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- XBiotech Inc. (NASDAQ: XBIT) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- XBiotech Inc. (NASDAQ: XBIT) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
XBIT
Sec Filings
- 3/15/24 - Form 10-K
- 2/7/24 - Form SC
- 2/7/24 - Form SC
- XBIT's page on the SEC website